January 13, 2021 -- Bayer highlighted its focus on cell, gene, and oncology pipelines during its virtual Pharma Media Day in Germany.
Bayer also will be pushing more than 50 projects that focus on cardiovascular diseases, oncology, and women's health. The company highlighted two promising pipeline programs in mid-stage development: Factor XI (FXI)-targeting compounds, which are a new class of anticoagulants that is comprised of three investigational assets, and an anti-FXIa antibody and a FXI-ligand-conjugated antisense oligonucleotide (FXI-LICA) that are being studied in patients with end-stage kidney disease. FXI-pathway inhibition may offer protection from thromboembolic events without increased risk of bleeding.
Copyright © 2021 scienceboard.net